Genelux Corporation (NASDAQ: GNLX) Stock Information | RedChip

Genelux Corporation (NASDAQ: GNLX) Listen to this Section


$2.03
-0.1000 ( -4.69% ) 60.6K

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Market Data


Open


$2.03

Previous close


$2.13

Volume


60.6K

Market cap


$69.39M

Day range


$2.02 - $2.16

52 week range


$1.60 - $30.44

Insider Ownership Transactions

Total Amount Purchased: -417,531.00 | $ -847,587.93

Date Type Amount Purchased Purchaser
2023-09-15 Sale -250000.00 Zindrick Thomas
2023-09-14 Sale -900.00 Smither John W
2023-09-13 Sale -6920.00 Smither John W
2023-09-13 Sale -9331.00 Szalay Aladar
2023-09-13 Sale -3460.00 Thomas John
2023-09-13 Sale -3460.00 Mirabelli Mary
2023-09-13 Sale -3460.00 Tyree James L
2023-09-12 Sale -65000.00 Yu Yong
2023-09-12 Sale -65000.00 Cappello Joseph
2023-09-12 Sale -10000.00 Smalling Ralph

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Oct 16, 2023
4 Insider transactions 1 Oct 11, 2023
4 Insider transactions 1 Oct 10, 2023
8-k 8K-related 52 Oct 10, 2023
4 Insider transactions 1 Oct 04, 2023
4 Insider transactions 1 Oct 04, 2023
4 Insider transactions 1 Sep 29, 2023
4 Insider transactions 1 Sep 27, 2023
4 Insider transactions 1 Sep 27, 2023
4 Insider transactions 1 Sep 25, 2023

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.